{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:47:11Z","timestamp":1760453231424,"version":"3.44.0"},"reference-count":19,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,11,17]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>Chemotherapy-induced hypertriglyceridaemia (HTG) is a potential serious adverse event. Severe HTG with triglycerides (TG) &gt;11.3\u2009mmol\/L (1000\u2009mg\/dL) can cause acute pancreatitis in addition to cardiovascular diseases such as coronary artery disease. While the association of capecitabine (5-fluorouracil (5-FU) prodrug) with clinically relevant HTG is a well-known adverse reaction, 5-FU is not typically associated with HTG. We here report the case of a patient who developed 5-FU-associated grade 4 HTG with TG level raising up to 37.1\u2009mmol\/L (3286\u2009mg\/dL) occurring after the ninth cycle of adjuvant FOLFOX (Fluorouracil and Oxaliplatin) chemotherapy. Fenofibrate treatment and diet were started. Chemotherapy was postponed and then resumed for two additional cycles. However, severe HTG recurred shortly after. Chemotherapy was therefore permanently stopped. Approximately 8 weeks after chemotherapy discontinuation, TG fell back to range at 2.1\u2009mmol\/L (189\u2009mg\/dL) allowing interruption of fenofibrate without HTG recurrence at 3 months.<\/jats:p>","DOI":"10.1136\/bcr-2023-254871","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T12:40:26Z","timestamp":1702989626000},"page":"e254871","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["5-Fluorouracil-associated severe hypertriglyceridaemia with positive rechallenge"],"prefix":"10.1136","volume":"16","author":[{"given":"Bianca","family":"Giacomuzzi Moore","sequence":"first","affiliation":[{"name":"Oncology, CHUV, Lausanne, Switzerland"},{"name":"Oncology, Hopital Riviera-Chablais, Rennaz, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Durigova","sequence":"additional","affiliation":[{"name":"Oncology, Hopital Riviera-Chablais, Rennaz, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiza","family":"Lamine","sequence":"additional","affiliation":[{"name":"Endocrinology and Diabetes Unit, Internal Medicine Department, Hopital Riviera-Chablais, Rennaz, Switzerland"},{"name":"Endocrinology, Diabetology and Metabolism, CHUV, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haithem","family":"Chtioui","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Service, University Hospital, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Salati","sequence":"additional","affiliation":[{"name":"Oncology, Hopital Riviera-Chablais, Rennaz, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"2025082803073614000_16.12.e254871.1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0799-2"},{"key":"2025082803073614000_16.12.e254871.2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G348"},{"key":"2025082803073614000_16.12.e254871.3","first-page":"2249","article-title":"Capecitabine-induced hypertriglyceridemia: a report of two cases","volume":"26","author":"Koutras","year":"2006","journal-title":"Anticancer Res"},{"key":"2025082803073614000_16.12.e254871.4","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214532508"},{"key":"2025082803073614000_16.12.e254871.5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605807"},{"key":"2025082803073614000_16.12.e254871.6","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.21037\/jgo.2018.07.07","article-title":"Capecitabine-induced hypertriglyceridemia: a rare but clinically relevant treatment-related adverse event","volume":"9","author":"Uche","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"2025082803073614000_16.12.e254871.7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000512820","article-title":"Hypertriglyceridemia induced by fluorouracil: a novel case report","volume":"14","author":"Saito","year":"2021","journal-title":"Case Rep Oncol"},{"key":"2025082803073614000_16.12.e254871.8","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/1078155220956691","article-title":"Hypertriglyceridemia induced by S-1: a novel case report and review of the literature","volume":"27","author":"Saito","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"2025082803073614000_16.12.e254871.9","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00184"},{"key":"2025082803073614000_16.12.e254871.10","doi-asserted-by":"publisher","DOI":"10.3109\/02841869509093964"},{"key":"2025082803073614000_16.12.e254871.11","doi-asserted-by":"crossref","first-page":"57290","DOI":"10.18632\/oncotarget.10145","article-title":"Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"2025082803073614000_16.12.e254871.12","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14371"},{"key":"2025082803073614000_16.12.e254871.13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2478\/abm-2010-0079","article-title":"Oral fluoropyrimidine-induced severe hyperlipidemia","volume":"4","author":"Yildiz","year":"2010","journal-title":"Asian Biomed (Res Rev News)"},{"key":"2025082803073614000_16.12.e254871.14","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s11096-021-01324-0","article-title":"Fluoropyridmidine use and hypertriglyceridemia among Japanese patients: analysis of adverse event database","volume":"44","author":"Mitsuboshi","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"2025082803073614000_16.12.e254871.15","doi-asserted-by":"crossref","first-page":"60704","DOI":"10.18632\/oncotarget.19610","article-title":"Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy","volume":"8","author":"Gou","year":"2017","journal-title":"Oncotarget"},{"key":"2025082803073614000_16.12.e254871.16","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp110144"},{"key":"2025082803073614000_16.12.e254871.17","first-page":"1242","article-title":"Heparin and insulin in the treatment of acute hypertriglyceridemia-induced pancreatitis","volume":"129","author":"Henzen","year":"1999","journal-title":"Schweiz Med Wochenschr"},{"key":"2025082803073614000_16.12.e254871.18","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.15.8.1086"},{"key":"2025082803073614000_16.12.e254871.19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0022-2275(20)41211-8","article-title":"Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation","volume":"35","author":"Weintraub","year":"1994","journal-title":"J Lipid Res"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-254871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:07:42Z","timestamp":1756375662000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-254871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,19]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/bcr-2023-254871"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-254871","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}